Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy": Six analysts give PAHC a consensus rating of Moderate Buy (1 sell, 2 hold, 2 buy, 1 strong buy) with an average 12‑month target of $37.50, while the stock opened at about $57.89 on the reported day.
• Quarterly beat and guidance: Phibro reported EPS of $0.87 vs. $0.69 expected and revenue of $373.9M (vs. $355.6M expected), and set FY2026 guidance of 2.930–3.100 EPS.
• Insider selling: CEO Jack Bendheim sold 110,842 shares (~$5.36M) in February and insiders sold 316,259 shares in the last 90 days, though insiders still own about 50.13% of the company.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $37.50.

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a "buy (b-)" rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research report on Friday, February 6th. Finally, Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 11th.

Phibro Animal Health Trading Down 2.0%

Shares of PAHC stock opened at $57.89 on Friday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $59.67. The stock has a fifty day moving average of $52.23 and a two-hundred day moving average of $44.49. The firm has a market capitalization of $2.35 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 0.89 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, research analysts expect that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th were given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Wednesday, March 4th. Phibro Animal Health's payout ratio is 21.33%.

Insider Transactions at Phibro Animal Health

In other news, CEO Jack Bendheim sold 110,842 shares of the company's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96. Following the completion of the sale, the chief executive officer owned 122,958 shares in the company, valued at $5,948,708.04. This represents a 47.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 316,259 shares of company stock worth $15,256,865. Insiders own 50.13% of the company's stock.

Institutional Trading of Phibro Animal Health

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company's stock valued at $57,519,000 after buying an additional 13,884 shares during the period. State Street Corp lifted its holdings in shares of Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company's stock valued at $35,204,000 after buying an additional 48,243 shares during the period. Millennium Management LLC lifted its holdings in shares of Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company's stock valued at $23,959,000 after buying an additional 626,492 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Phibro Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company's stock valued at $21,265,000 after buying an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Phibro Animal Health by 1.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company's stock valued at $18,394,000 after buying an additional 6,826 shares during the period. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.